Karyopharm Therapeutics (KPTI) Competitors $0.78 0.00 (0.00%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends KPTI vs. BTAI, KALV, VALN, AMLX, DNA, ALEC, QTTB, CTNM, KMDA, and TKNOShould you be buying Karyopharm Therapeutics stock or one of its competitors? The main competitors of Karyopharm Therapeutics include BioXcel Therapeutics (BTAI), KalVista Pharmaceuticals (KALV), Valneva (VALN), Amylyx Pharmaceuticals (AMLX), Ginkgo Bioworks (DNA), Alector (ALEC), Q32 Bio (QTTB), Contineum Therapeutics (CTNM), Kamada (KMDA), and Alpha Teknova (TKNO). These companies are all part of the "pharmaceutical products" industry. Karyopharm Therapeutics vs. BioXcel Therapeutics KalVista Pharmaceuticals Valneva Amylyx Pharmaceuticals Ginkgo Bioworks Alector Q32 Bio Contineum Therapeutics Kamada Alpha Teknova Karyopharm Therapeutics (NASDAQ:KPTI) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, community ranking, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations. Which has stronger valuation & earnings, KPTI or BTAI? Karyopharm Therapeutics has higher revenue and earnings than BioXcel Therapeutics. Karyopharm Therapeutics is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioKaryopharm Therapeutics$146.03M0.67-$143.10M-$1.14-0.68BioXcel Therapeutics$1.38M18.22-$179.05M-$2.16-0.27 Do insiders & institutionals believe in KPTI or BTAI? 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 4.3% of Karyopharm Therapeutics shares are owned by insiders. Comparatively, 28.7% of BioXcel Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Does the MarketBeat Community prefer KPTI or BTAI? Karyopharm Therapeutics received 292 more outperform votes than BioXcel Therapeutics when rated by MarketBeat users. Likewise, 72.30% of users gave Karyopharm Therapeutics an outperform vote while only 67.50% of users gave BioXcel Therapeutics an outperform vote. CompanyUnderperformOutperformKaryopharm TherapeuticsOutperform Votes53572.30% Underperform Votes20527.70% BioXcel TherapeuticsOutperform Votes24367.50% Underperform Votes11732.50% Is KPTI or BTAI more profitable? Karyopharm Therapeutics has a net margin of -58.93% compared to BioXcel Therapeutics' net margin of -3,119.33%. Company Net Margins Return on Equity Return on Assets Karyopharm Therapeutics-58.93% N/A -41.25% BioXcel Therapeutics -3,119.33%N/A -105.04% Do analysts prefer KPTI or BTAI? Karyopharm Therapeutics currently has a consensus target price of $5.00, suggesting a potential upside of 545.16%. BioXcel Therapeutics has a consensus target price of $5.00, suggesting a potential upside of 750.34%. Given BioXcel Therapeutics' higher possible upside, analysts clearly believe BioXcel Therapeutics is more favorable than Karyopharm Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Karyopharm Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00BioXcel Therapeutics 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Does the media refer more to KPTI or BTAI? In the previous week, Karyopharm Therapeutics and Karyopharm Therapeutics both had 4 articles in the media. Karyopharm Therapeutics' average media sentiment score of 0.78 beat BioXcel Therapeutics' score of 0.25 indicating that Karyopharm Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Karyopharm Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioXcel Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility and risk, KPTI or BTAI? Karyopharm Therapeutics has a beta of 0.16, suggesting that its share price is 84% less volatile than the S&P 500. Comparatively, BioXcel Therapeutics has a beta of 0.29, suggesting that its share price is 71% less volatile than the S&P 500. SummaryKaryopharm Therapeutics beats BioXcel Therapeutics on 11 of the 16 factors compared between the two stocks. Ad Crypto Swap Profits[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.Register for the FREE Workshop Now & get $10 in Bitcoin Get Karyopharm Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KPTI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KPTI vs. The Competition Export to ExcelMetricKaryopharm TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$97.12M$6.45B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E Ratio-0.6810.78126.3117.81Price / Sales0.67243.711,178.7474.57Price / CashN/A22.1633.8632.53Price / Book-0.655.474.684.68Net Income-$143.10M$153.61M$119.54M$226.08M7 Day Performance-7.44%-2.00%-1.83%-1.04%1 Month Performance-9.29%-7.46%-3.60%1.04%1 Year Performance4.99%31.82%31.91%26.28% Karyopharm Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KPTIKaryopharm Therapeutics3.9896 of 5 stars$0.78flat$5.00+545.2%-1.5%$96.87M$146.03M-0.68380BTAIBioXcel Therapeutics4.5124 of 5 stars$0.59-1.7%$5.00+750.3%-84.6%$25.14M$1.38M-0.2790Gap DownKALVKalVista Pharmaceuticals3.7118 of 5 stars$8.96-1.0%$26.00+190.2%+9.1%$387.25MN/A-2.54150Insider TradeNews CoverageVALNValneva2.2761 of 5 stars$4.67+2.4%$18.50+296.1%-62.1%$370.49M$165.52M0.00700AMLXAmylyx Pharmaceuticals4.3606 of 5 stars$5.23+0.2%$11.43+118.5%-59.5%$358.51M$196.49M-1.37200Analyst UpgradeDNAGinkgo Bioworks1.1347 of 5 stars$6.36-1.4%$4.58-28.1%N/A$358.46M$251.46M0.001,218Short Interest ↓ALECAlector4.4456 of 5 stars$3.64-5.7%$20.67+468.5%-26.1%$355.99M$61.51M-2.23270Positive NewsQTTBQ32 Bio1.6079 of 5 stars$27.28-6.2%$72.33+165.2%N/A$354.34M$1.16M0.0039CTNMContineum Therapeutics1.6382 of 5 stars$13.65+2.6%$29.25+114.3%N/A$351.90M$50M0.0031KMDAKamada3.8063 of 5 stars$5.82-1.5%$14.50+149.1%+23.3%$339.70M$142.52M20.79360Analyst RevisionTKNOAlpha Teknova0.7125 of 5 stars$7.74+24.6%$5.00-35.4%+279.4%$331.04M$36.68M0.00240Gap UpHigh Trading Volume Related Companies and Tools Related Companies BioXcel Therapeutics Competitors KalVista Pharmaceuticals Competitors Valneva Competitors Amylyx Pharmaceuticals Competitors Ginkgo Bioworks Competitors Alector Competitors Q32 Bio Competitors Contineum Therapeutics Competitors Kamada Competitors Alpha Teknova Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:KPTI) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Karyopharm Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
